A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. on behalf of investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026. The lawsuit, filed in the United States District Court for the District of New Jersey, alleges that the company made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. The complaint follows a March 24, 2026 report by Culper Research that accused ADMA of channel stuffing and an undisclosed related party distributor, causing the stock to fall 29.1% over two days to close at $9.63 per share on March 25, 2026. Investors have until August 10, 2026 to seek appointment as lead plaintiff through counsel such as Kessler Topaz Meltzer & Check, LLP.
ADMA Biologics IncSecurities fraud class action lawsuit alleging false statements, channel stuffing, and inadequate internal controls.
ServiceNow Inc